XFOR — X4 Pharmaceuticals, Inc.

Summary of X4 Pharmaceuticals Q1 2025 Earnings Call

1. Key Financial Results and Metrics:

• Cash Position: X4 ended Q1 2025 with approximately $90 million in cash and cash equivalents, expected to support operations into the first half of 2026.
• Revenue: Net revenues from XOLREMDI were just under $1 million for Q1 2025, bringing cumulative sales since its launch in May 2024 to about $3.5 million.
• Expenses: R&D expenditures totaled $18.5 million, while SG&A expenses were $15 million.
• Net Income: The company reported a small net income due to $28 million in license revenue from Norgine and a $10.8 million gain on Class C warrants.

2. Strategic Updates and Business Highlights:

• Clinical Trials: X4 is advancing its pivotal Phase III trial (4WARD) for mavorixafor in chronic neutropenia (CN), targeting a high unmet need population. Enrollment is ongoing in over 20 countries with over 90% of sites activated.
• Regulatory Progress: The company received a notice of allowance for a patent covering mavorixafor for treating severe chronic idiopathic and autoimmune neutropenia, expiring in March 2041.
• Commercialization of XOLREMDI: Cumulative sales reached $3.5 million, with efforts ongoing to increase visibility and demand through educational programs and partnerships, including agreements with Norgine and taiba rare for commercialization in Europe and the MENA region, respectively.

3. Forward Guidance and Outlook:

• Enrollment Expectations: Full enrollment for the 4WARD trial is anticipated in Q3 or Q4 of 2025, with top-line data expected in the second half of 2026.
• Market Potential: The company estimates a $1 billion to $2 billion market opportunity for mavorixafor in the CN indication in the US alone.

4. Bad News, Challenges, or Points of Concern:

• Sales Fluctuation: Q1 sales of XOLREMDI were lower than in Q4 2024 due to inventory resupply timing, reflecting the volatility typical in small patient populations.
• Patient Enrollment: While there is strong interest from physicians to enroll patients in the 4WARD trial, the strict eligibility criteria may limit the number of patients who can participate.
• Market Competition: The company faces challenges in establishing a foothold in a competitive market with limited patient populations and treatment options.

5. Notable Q&A Insights:

• Patient Enrollment: The enrollment profile for the 4WARD trial is strong, with a focus on very sick patients, which aligns with the high unmet need in the CN market.
• Compliance and Persistence: Early indications show higher than expected compliance rates for XOLREMDI, attributed to the significant unmet need among patients.
• Market Research: Insights from a survey of US physicians treating chronic neutropenia indicate a higher concentration of patients compared to WHIM syndrome, suggesting a more defined market opportunity.

Overall, X4 Pharmaceuticals is making significant strides in its clinical and commercial efforts, although it faces challenges related to sales fluctuations and patient enrollment criteria. The company remains optimistic about its future potential in the chronic neutropenia market.